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Leiomyomas represent the most common type of benign tumors of the female 
genital tract. Assiduous preoperative imaging findings reflect proper therapeutic 
mapping. In cases of female patients of reproductive age, the ultimate goal remains 
the fertility preservation and the quality of life of the patient. According to recent 
bibliography, bizarre leiomyomas remain a controversial issue regarding the preop-
erative and postoperative therapeutic mapping. Giant cells with pleomorphic nuclei 
and little or no mitotic activity compose the microscopic analysis of such lesions. 
Multidisciplinary approach is mandatory in order to establish ultimate diagnosis 
and treatment. Bizarre leiomyomas still represent a gray scale among the whole 
scientific community.
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1. Introduction
The incidence of uterine fibroid tumors increases as women grow older, and 
they may occur in more than 30% of women 40–60 years of age (Figure 1). Risk 
factors include null parity, obesity, family history, black race, and hypertension.
Many tumors are asymptomatic and may be diagnosed incidentally. Many stud-
ies have indicated the proper therapeutic mapping in cases of nulliparous young 
patients.
Therapeutic strategy is strongly accompanied with age and fertility capacity of 
the patient. In cases of degenerated uterine fibroids in nulliparous patients, laparo-
scopic approach represents the gold standard of surgical confrontation.
In reproductive age women, 15–30% of these tumors are responsible for men-
strual disorders, anemia due to perfuse uterine bleeding, pelvic pain, pregnancy 
loss, rarely preterm birth, and percentage of infertility [1].
In order to establish a proper diagnosis and treatment, especially in women of 
reproductive age, there is a classification of uterine fibroids [2].
Major categories consist of submucosal, intramural, subserosal, and others 
(cervical, parasitic) (Table 1).
Many factors affect the therapeutic mapping of uterine myomas. Age of the 
patient, gynecologic or obstetrical history, previous surgical procedures and fertil-
ity preservation.
Uterine fibroids consist of smooth muscular tissue with always the possibility of 
malignant transformation. Tumor size and anatomic location are strongly accompa-




Classification of uterine fibroids. Women’s Health 2014. Future Medicine Ltd.
Figure 1. 
Uterine fibroids. newsnetwork.mayoklinic.org.
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Figure 2. 
Abdominal MRI with enlarged uterine fibroid depiction. Researchgate.net.
Figure 3. 
Uterine fibroid embolization. Interventionalnews.com.
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Transvaginal ultrasonography reflects the first preoperative procedure, depending 
on the physician’s experience and technical sufficiency of the ultrasound machine.
Imaging findings as areas of cystic degeneration, enlarged and asymmetric 
vascularization, papillary protrusions, and possibly increased tumor markers as 
Ca-125/Ca 15-3/Ca 19-9 reveal preoperative procedures of malignant metaplasia [3].
In such cases, abdominal MRI can, without a doubt, guide the preoperative 
management [4] (Figure 2).
In order to avoid diffuse menorrhagia and procedures of diffuse intravascular 
coagulation, an appropriate solution consists of uterine fibroid embolization [5]. 
With the use of colloid substances, we can lead to fibroid necrosis and cell apoptosis 
(Figure 3).
There are cases after fibroid surgical dissection and abdominal or vaginal 
hysterectomy where the histopathologic evaluation confirms bizarre myomas. The 
dilemma is controversial especially in cases of female patients of reproductive age. 
The ultimate goal remains fertility preservation of such patients.
2. Discussion
All mentioned scientific guidelines reflect the pathway from general depictions 
of uterine anatomy and physiology to specific fibroid pathology.
Many authors complete their monograph concerning uterine fibroids. They 
described several tumors with similar macroscopic view as uterine fibroid, but 
microscopically they include large multinucleated tumor cells.
After WHO (World Health Organization) classification bizarre leiomyomas 
presented as fibroids with giant cells with pleomorphic nuclei and little or no mitotic 
activity [6].
In many cases they represent a histologic gray zone concerning the therapeutic 
mapping in female patients of reproductive age.
Before final diagnosis is established, assiduous examination of the specimen is 
mandatory focusing on terms of atypia or necrosis (simple, moderate, or severe).
Along with genetic predisposition and ovarian hormone stimulation, many 
growth factors are identified.
Besides genetic predisposition and ovarian hormones that play a major role in 
tumor expansion, a large number of growth factors have also been identified which 
favor expansion.
These are insulin-like growth factor (IGF), epidermal growth factor (EGF) and 
platelet-derived growth factor (PDGF), transforming growth factor beta (TGF 
beta), and basic fibroblast growth factor (BFGF) [7]. These may have a role to play 
in tumor expansion.
The major differential dilemma remains the establishment of bizarre uterine 
myomas versus endometrial stromal sarcoma (ESS) (Figure 4).
The main characteristics of ESS consist of infiltrative myometrium growth and 
vascular invasion, presence of necrotic areas, and mitotic activity [8].
Due to infiltration of the myometrial basal membrane, surgical dissection after 
staging of the lesion represents the gold standard. Multidisciplinary approach is 
mandatory in order to establish proper postoperative treatment.
In cases of metastatic ESS, neoadjuvant therapy or series of radiotherapy  
will understage the tumor expansion and make the tumor staging  
surgically feasible.
On the other hand, patients with positive progesterone or estrogen receptors 
(ER+, PR+), can be treated postoperatively with hormonal agents such as progesto-
gens [9].
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Ki-67 as exceptional biomarker is strongly accompanied with proliferative activ-
ity and presence of necrotic areas. Many conducted studies have adjusted Ki-6 and 
successful postoperative management.
In primary stages of the lesion, fertility preservation in female patients of 
reproductive age remains a controversial dilemma [10].
The impact of bizarre leiomyoma on fertility is not well known. Bizarre leio-
myoma consists of a rare entity composing pleomorphic or symplastic cells which 
require assiduous histopathologic evaluation.
If fertility preservation is not required, the standard surgical intervention for 
bizarre leiomyoma that shows a benign clinical course is a simple hysterectomy 
[11, 12].
Due to rare incidence of bizarre myomas, in cases of female patients of repro-
ductive age with ultimate scope the fertility preservation, simple myomectomy as 
the gold standard remains a controversial issue.
Etiology concerning this issue depends on the identification difficulty during 
myomectomy between specimen surgical borders and myometrium. After histo-
pathologic evaluation and not clear surgical margins, there is an increased incidence 
of tumor recurrence [13].
On the other hand, surgical treatment with dissection part of the associated 
myometrium, can lead in a future pregnancy, to spontaneously membrane rupture 
and episodes of preterm birth.
Precise scientific evaluation of current bibliography, focusing on optimal treat-
ment in patients of reproductive age, reveals a lack of scientific guidelines.
Figure 4. 
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The ultimate scope of the above presentation reflects the stimulus of completion 
and composition new conducted studies, which will guide assiduously and clear all 
controversial issues.
Bizarre uterine myomas, as rare entity, still represent a gray area among the 
whole scientific society.
3. Conclusion
Bizarre uterine fibroids represent a controversial scientific zone in the current 
bibliography. More studies must be conducted in order to establish proper diagnosis 
and treatment.
Multidisciplinary approach is mandatory in cases of patients of reproductive 
age. The ultimate goal remains in such cases, always fertility preservation.
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